Brief: Theranexus Announces German Authorities Approval For Its Phase 2 Clinical Trial In Parkinson's Disease

Thx Pharma SA

26/06/2018 06:34

June 26 (Reuters) - THERANEXUS SA  ALTHX.PA :
    * ANNOUNCES GERMAN AUTHORITIES APPROVAL FOR ITS PHASE 2
CLINICAL
TRIAL IN PARKINSON'S DISEASE
    * RESULTS OF THIS STUDY ARE EXPECTED IN Q2 OF 2019
    * STUDY AIMS TO EVALUATE CLINICAL BENEFIT OF DRUG CANDIDATE
THN102
IN 60 PATIENTS SUFFERING FROM PARKINSON'S DISEASE AS WELL AS
FROM EDS
    * THERANEXUS HAS NOW OBTAINED A FURTHER EUROPEAN APPROVAL
FOR ITS
MULTICENTRE CLINICAL STUDY WHICH WILL BE CONDUCTED IN MORE THAN
20 CENTRES IN FIVE COUNTRIES (UNITED STATES, FRANCE, GERMANY,
HUNGARY, CZECH REPUBLIC)

Source text for Eikon:  ID:nACT53911 
Further company coverage:  ALTHX.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))